SILO

Silo Pharma, Inc.
CAPPED RATING

Silo Pharma, Inc. (SILO) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.1 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D-
Factor Score 1.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.6
EV / EBITDA 0.5
Rev Growth YoY N/A
Gross Margin -14.8%
Price Return 3M -40.1%
Price Return 12M -72.8%
Catalyst Signal 0.00
Market Cap $4.3M
TTM Revenue $54.1K
Price / Sales 79.6
ROE -91.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.1) C+ (2.5) C- (2.0) D- (1.0) C+ (2.6) C (2.3)
2026-11-07 B (3.3) C+ (2.5) C- (2.0) F (0.6) C+ (2.7) C (2.2)
2026-10-31 B (3.2) C+ (2.5) C- (1.9) F (0.5) C+ (2.7) C- (2.1)
2026-10-24 B (3.2) C+ (2.5) D+ (1.8) F (0.5) C+ (2.6) C- (2.1)
2026-10-17 B (3.2) C+ (2.5) D+ (1.8) F (0.4) C+ (2.6) C- (2.1)
Page 1 of 4